New Insights into Chemoresistance Mediated by Mdm2 Inhibitors: The Benefits of Targeted Therapy over Common Cytostatics

• Published in: Biomedicines Vol. 12; no. 3; p. 547
• Main Authors: Grigoreva, Tatyana, Sagaidak, Aleksandra, Novikova, Daria, Tribulovich, Vyacheslav
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 29.02.2024; MDPI
• Subjects: Antimitotic agents; Antineoplastic agents; Biotechnology industry; Cancer; Care and treatment; Cell cycle; Chemoresistance; Chemotherapy; cytostatics; Cytotoxicity; Development and progression; Drug resistance; Drug therapy; Drugs; Glycoproteins; MDM2 protein; MDR; Medical research; Mutation; Nutlin-3a; P-glycoprotein; p53 Protein; Paclitaxel; Proteins; Reagents; Statistical analysis; Tumor cells; Tumor proteins; Russia; United States > US; BCRP; P-glycoprotein; paclitaxel; MDR; drug resistance; Nutlin-3a; cytostatics

The inhibition of the Mdm2-p53 protein-protein interaction is a promising strategy for anticancer therapy. However, the problem of developing secondary chemoresistance in tumors treated with such drugs has not yet been sufficiently studied. In this work, we compared the properties of a drug-resistan...